"Creatinine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D003404
|
| MeSH Number(s) |
D03.383.129.308.207
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Creatinine".
Below are MeSH descriptors whose meaning is more specific than "Creatinine".
This graph shows the total number of publications written about "Creatinine" by people in this website by year, and whether "Creatinine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Creatinine" by people in Profiles.
-
Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023 10 03; 78(10):2435-2441.
-
Validation of Vancomycin Dosing Guidance During Transition of Care. J Clin Pharmacol. 2021 06; 61(6):806-809.
-
Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 09; 104(3):534-538.
-
Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 11; 61(11).
-
Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 01; 61(1).
-
Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4.
-
Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012 Sep; 56(9):4625-9.
-
Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation. J Urol. 2012 May; 187(5):1739-46.